Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 16/20 | 0.58 |
| ▸ | ICAM1 | P05362 | 16/20 | 0.58 |
| ▸ | ITGAL | P20701 | 16/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.42 |
| ▸ | CCKAR | P32238 | 1/20 | 0.42 |
| ▸ | CCKBR | P32239 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10129729 | 0.88 | ITGB2 (0.74) | ITGB2ICAM1ITGALCYP2C9HDAC6 | |
| SCHEMBL18867798 | 0.80 | ITGB2 (0.62) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL12054462 | 0.78 | ITGB2 (0.71) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL4755918 | 0.77 | ITGB2 (0.72) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL28730926 | 0.77 | ITGB2 (0.52) | ITGB2ICAM1ITGALCYP2C9HDAC6 | |
| SCHEMBL28730924 | 0.77 | ITGB2 (0.52) | ITGB2ICAM1ITGALCYP2C9HDAC6 | |
| SCHEMBL19157809 | 0.76 | ITGB2 (0.76) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL20833626 | 0.76 | ITGB2 (0.76) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL18868628 | 0.76 | ITGB2 (0.78) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL19158574 | 0.76 | ITGB2 (0.73) | ITGB2ICAM1ITGALCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3797775-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | Novartis AG (CH) | 2021-03-31 | — | — | EP | disclosed |
| EP-3167886-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF MACULAR EDEMA | SARcode Bioscience Inc. (US) | 2017-05-17 | — | — | EP | disclosed |